Citigroup Increases ArriVent BioPharma (NASDAQ:AVBP) Price Target to $45.00

Key Points

• Citigroup raised its price target on ArriVent BioPharma (NASDAQ:AVBP) from $33 to $45.00 and kept a "buy" rating, implying roughly a 44.8% upside from the current share price.
• Other analysts are largely positive — several firms have "buy"/"strong-buy" ratings and raised targets into the mid‑$40s, leaving a MarketBeat consensus of "Moderate Buy" with an average target of $43.00.
• AVBP trades near $31.08 with a $1.37B market cap; it reported quarterly EPS of -$0.78 (beating estimates) and remains a clinical‑stage biopharma progressing trials for Furmonertinib.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) had its target price raised by stock analysts at Citigroup from $33.00 to $45.00 in a report issued on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. Citigroup's target price points to a potential upside of 44.79% from the stock's current price.

A number of other brokerages also recently weighed in on AVBP. BTIG Research assumed coverage on shares of ArriVent BioPharma in a research report on Thursday, March 12th. They set a "buy" rating and a $42.00 price objective for the company. Truist Financial raised shares of ArriVent BioPharma to a "strong-buy" rating in a research report on Wednesday, March 25th. B. Riley Financial boosted their price objective on shares of ArriVent BioPharma from $37.00 to $45.00 and gave the company a "buy" rating in a research report on Monday, March 23rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ArriVent BioPharma in a research report on Monday. Finally, HC Wainwright boosted their price objective on shares of ArriVent BioPharma from $42.00 to $44.00 and gave the company a "buy" rating in a research report on Friday, March 6th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $43.00.

ArriVent BioPharma Stock Performance

Shares of ArriVent BioPharma stock traded up $0.08 during trading on Friday, reaching $31.08. The company had a trading volume of 62,781 shares, compared to its average volume of 494,805. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -7.03 and a beta of 0.85. The firm's fifty day moving average is $24.76 and its 200-day moving average is $22.43. ArriVent BioPharma has a fifty-two week low of $16.10 and a fifty-two week high of $32.14.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($0.78) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.09. On average, research analysts anticipate that ArriVent BioPharma will post -3.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of ArriVent BioPharma by 27.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,006 shares of the company's stock valued at $40,000 after acquiring an additional 438 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of ArriVent BioPharma by 0.7% in the fourth quarter. Wellington Management Group LLP now owns 82,278 shares of the company's stock valued at $1,655,000 after acquiring an additional 532 shares in the last quarter. Woodline Partners LP boosted its holdings in shares of ArriVent BioPharma by 0.4% in the first quarter. Woodline Partners LP now owns 146,373 shares of the company's stock valued at $2,706,000 after acquiring an additional 576 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of ArriVent BioPharma by 4.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 14,743 shares of the company's stock valued at $297,000 after acquiring an additional 585 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of ArriVent BioPharma by 31.0% in the second quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company's stock valued at $56,000 after acquiring an additional 609 shares in the last quarter. 9.48% of the stock is currently owned by institutional investors.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.